Index

A
A-beta nerve fibres, 32
Advisory Committee on Prosthetics and Special Disabilities, 109
African continent, occurrence rates in amputation, 384
foot infection, 383–384
foot ulceration, 381–383
mortality, 384
neuroischaemia, 380
peripheral neuropathy, 380
peripheral vascular disease, 380
American Diabetes Association (ADA) consensus statement, 434
amitriptyline, 36
amputation surgery, principles of blood vessels, 325
bones, 326
muscle, 325
nerves, 325
post surgery, 326–327
skin, 325
wound dressing, 326
amputation, epidemiology of, 17. see also amputee rehabilitation
estimation of, 17–18
level selection, 310–311
hindfoot, 314
midfoot, 314
Syme’s ankle disarticulation, 321
toe, 311
and limb salvage, 308–309
management of knee disarticulation, 331–332
second limb, 333
Syme’s/ankle, 330
toes, 328
transfemoral, 333
transmetatarsal, 328
transtibial, 330–331
prevention programme, cost analysis of, 51
risk assessment, 433–436
risk factors for, 18
ethnicity, influence of, 22–25
major environmental, 19–20
socio-economic status and care provision, role of, 21
unalterable, 20–21
trends in, 21–22
in Germany, 51
in Netherlands, 51
amputee rehabilitation
post surgery, 326–327
pre-amputation phase, 324
psychological assessment, 327–328
surgical phase, 325
amyotrophy, see diabetic neuropathy, asymmetrical or focal
ankle-brachial pressure index (ABPI), 97, 434
antioxidant α-lipoic acid, 37
Aquacell, 191

B
biomechanics, 68
mechanisms of high pressure, in diabetic patients
activity profiles, 76–78
extrinsic factors, 76
intrinsic factors, 71–76
negative pressure wound therapy, 360–362
stress and stress concentrations, 68–70,
see also diabetic neuropathy
in treating a plantar ulcer, 83–85
bisphosphonates, 269–271
INDEX

C  
cadexomer iodine, 190  
carbamazepine, 36  
cardiac ankyrin repeat protein (CARP), 200  
Charcot neuroarthropathy (CN)  
clinical features, 267  
diagnosis, 268  
epidemiology, 265  
non-operative treatment of  
pharmacological, 269–271  
radiation therapy, 269  
ultrasound, 269  
operative treatment, of deformities  
ankle, 277–278  
forefoot, 278  
hindfoot deformity, 277  
midfoot deformity, 275–277  
persistent calcaneus, 278  
pathogenesis, 265–267  
Charcot restraint orthotic walker (CROW), 268, 299  
Charcot–Marie–Tooth syndrome, 226  
clinical practice guidelines (CPGs)  
appraisal instruments of, 405  
AGREE, 405–407  
choice of, 405  
diagnostic analysis of, 412–413  
implementation of  
baseline data collection, 413  
communication process, 414  
drafting and pre-testing, 413–414  
education interventions, 414–415  
for health care professionals, 410–411  
monitoring, 415  
for patients, 411  
plan, 414  
for referral practice, 411–412  
for stakeholders, 409–410  
integrating team of, 412  
common sense model (CSM) of illness behavior,  
see diabetic foot ulcers, psychosocial factors  

D  
dalbavancin, 179  
daptomycin, 179  
Diabetes Audit and Research in Tayside Scotland (DARTS) study, 52  
diabetic foot care service, see also  
multidisciplinary diabetic foot clinic  

communication pathways in, 427  
dedicated hot line services, 427  
patient held records, 428  
Exeter Diabetic Foot Care project approach  
integrated method, see integrated care pathway  
pathways in, 427  
primary care, 425–426  
referrals forms, role of, 427  
roles and settings of, 425  
satellite specialist clinics, establishment of, 428  
secondary care, 426  
staff training in, 428–429  
UK perspective  
follow up after screening, 127–128  
foot care screening, 126–127  
National Service Framework (NSF), 121–122  
new GP contract, 122–123  
NICE guideline, 123–126  
referral service, 129  
staff education, 130  
Veterans Health Administration (VHA) approach  
components of prevention and care, 110–113  
PACT programme, 108–109, 112  
risk assessment level, 111  
systems of care, 109–110  
diabetes quality indicator 10 (DM10), 123  
diabetic foot ulcers, see also foot infections, in  
diabetes persons; foot lesion classification systems; wound dressing, in diabetic person; wound treatment, in diabetes person  
in Africa, 381–383  
anatomic site of, 5  
assessment of risk, 57–60  
in Brazil, see Save the Diabetic Foot Project classification of, 1–2  
cost analysis for treatment of, 12–13  
hospital reimbursement, 13  
causal pathway to, 61  
definition of, 1–2  
disease onset, 2–5  
disease outcomes, 11–12  
frequency of lesion, 12  
educational programs for management of, see  
preventive foot care education program  
evidence based recommendations for, 398–403  
care pathway, algorithm of, 402  
continuing care, 399–401  
local health care, 401, 403
INDEX

in India
epidemiology, 375
footwear development, 377
management of care, 376–377
pathophysiology, 375–376
wound management tools, development of, 377
international working group on, 386–387
1999 consensus, 387
2003 consensus, 387–389
consensus implementation, 390–391
consensus process, 389–390
future projects of, 391
treatment guidelines for, 391–392
wound healing report on, 393–394
interventions to foot care, 68
caring services, see diabetes foot care service
classification systems, see foot lesion
classification systems
mechanical factors responsible for, 61–64
and microvascular defects, 47, see also microvascular diseases
offloading therapy for, see also wound
dressing, in diabetic person
charcot restraint orthotic walker (CROW), 299
felted foam padded dressings, 301–303
healing sandals and shoes, 299–301
patient activity, 305
removable cast walkers (RCW), 297–299
total contact cast (TCC), 293–297
therapeutic shoes and insoles, 303–304, 338–342
and peripheral vascular disease, 52
potential for, 425
prevalence, 2–5
psychosocial factors in
common sense model (CSM) of illness
behavior, 134–137
and major depression, 137–138
published studies, 134
quality of life, 138–140
systematic reviews, 132–133
risk assessment of, 431–433
risk factors for, 5–10, 55, see also amputation,
epidemiology of
age and duration of diabetes, 55
contributory, 433
cumulative, 433
deformity, 57
ethnic differences, 56
gender difference, 55
motor neuropathy, 56
oedema, 56
other microvascular complications, 56
plantar callus, 56
previous incidence, 55
surgery for
achilles tendon lengthening, 290
bone resection therapy, 287–289
closure techniques, 289–290
free tissue transfer therapy, 289
indications, 285–286
reconstruction of forefoot deformities, 290–291
toenail surgery, 291
wound debridement, 289–290
wound healing in, 48
parameters, 309–310
diabetic neuropathy see also amputation,
epidemiology of, risk factors for
acute painful, 33
pain management in, see pain management,
in painful diabetic neuropathy
asymmetrical or focal
proximal motor, 34–35
chronic sensorimotor, 53–54
determinants of, 30
distal symmetrical, 31
clinical presentation, 31
differential diagnosis, 33–34
natural history, 33
pathogenesis of, 35
reflexes in, 32
and high pressure, 70
mechanisms of, 70–78
influence in ulceration, 54–55
peripheral sympathetic autonomic, 54
primary prevention, 85–89
at risk examination, 81–82
2 minute foot examination, 78–81
30 second foot examination, 78–79
secondary prevention, 85–89
diabetic vascular disease, treatment of
treatment of background, 238–239
endovascular revascularization, 241–243
by percutaneous transluminal angioplasty (PTA), 238
complications in, 246–247
results of, 243–246
for thrombolysis, 247
vascular investigation, 238–239
foot lesion classification systems, 395–397

 aims and specification of
 clinical audit, 93
 clinical care, 92
 clinical research, 92–93
 component datasets
 individual characteristics, 96
 limb features, 97–99
 multiple criteria, 95–96
 ulcer/lesion features, 99–101
 factors classified
 at-risk foot, 93
 lesions, 93–94
 ulcers, 93–94
 wounds, 93

 ideal system of, 101

 published
 hybrid system, 104–105
 PEDIS system, 103–104
 S(AD) SAD system, 102–103
 University of Texas, 102

 timing of
 clinical audit, 94–95
 clinical care, 94
 clinical research, 94

 footwear design, for diabetic person
 correct
 for at risk patient, 343–344
 for Charcot patient, 345–346
 for newly diagnosed patient, 343
 for healed ulcer patient, 344–345
 for ulcer patient, 344
 from clinical trials and controlled studies, 337
 from experimental studies, 337–338
 from retrospective studies, 337
 therapeutic footwears
 compliance in wearing, 346
 cushioning in, 339
 load distribution in, 341–342
 load relief in, 339–341
 outsoles in, 342
 trends, 346
 fusidic acid, 179

 G
 gabapentin, 36
 general practitioner contract, see diabetes foot care service, UK perspective
 glyceryl trinitrate patch, 37
 Granuflex, 190
INDEX

granulocyte-colony-stimulating factors (G-CSFs), 165
ground reaction force (GRF), 311

H
haemodynamic hypothesis, 41–42
health maintenance organisation (HMO), 12
Healthcare Cost and Utilization Project, 5
high-risk foot registry, 109
HoxA3, 200
hyperbaric oxygen (HBO) therapy, 165

I
imaging appearances and techniques, of diabetic foot complications
computerised radiography (CR), 222
direct digital radiography (DDR), 222
effect of radiation exposure, 224–225
evidence of traumatic fractures, 226
of infections, 229–231
magnetic resonance imaging, 231–235
neuroarthropathic changes, 226–229
neuropathic changes, 226–229
radiological manifestations, 223
role of radiologist, 223
variation in appearances, 225–226
and vascular disease, 226
imipramine, 36
integrated care pathway
impact of, 118–119
initial evaluation, 117
roll out of the model, 118
International Classification of Diseases (ICD-9) codes, 5
International Working Group on the Diabetic Foot (IWGDF), 1, 100, see also diabetic foot ulcers, impaired vasoconstrictive reflexes
interstitial oedema, see microvascular disease, impaired vasoconstrictive reflexes
intra-arterial digital subtraction angiography (DSA), 239
intravenous lignocaine, 37
inverse care law, 21
Ionising Radiation (Medical Exposures) Regulations–IR(ME)R, 225
ischaemic heart disease (IHD), see amputation, epidemiology of, risk factors for isosorbide dinitrate spray, 37

K
Kaltostat, 191

L
larval therapy
maggots, clinical application of, 208–212
and antibiotic treatment, 209
application of, 208–209
duration of, 209
effect of, 208
effect on healthy tissue, 210
functioning of, 208
preservation of, 211
side effects of, 210
types of, 208
and wound odour, 210
LDIflare area, 46
lesion narrative, 95
linear no threshold (LNT) hypothesis, 224
loss of protective sensation (LOPS), 68, 70
low ankle–arm index (AAI), 6
Lower Extremity Amputation Study (LEAS) group protocol, 369

M
macrolides, 179
Manuka honey, 188
Meggitt–Wagner system, 101
Mesitran, 188
metatarsal head (MTH), 69
metatarsophalangeal joint (MTPJ), 287
microvascular diseases
axon reflex, 44–46
vasodilatory neuropeptides, release of, 44–45
capillary steal, 43–44
endothelium (dependent/independent)
vasodilation, 44–46
impaired microvascular responses, 42–43
techniques to identify, 43
impaired vasoconstrictive reflexes, 44
increased resting blood flow, 43–44
other functional abnormalities, 42
small vessel disease, 41
multidisciplinary diabetic foot clinic aims of, 418–419
clinical staff and their roles in, 421
location of, 419–420
purpose of, 420
support staff of, 422
time table for, 422–423

N
National Service Framework (NSF), 116, 121
negative pressure wound therapy, 360–362
neuropathy deficit score (NDS), 6
Neuropen®, 9
Neurotip®, 9
NICE guidelines, for primary care, see diabetes foot care service, UK perspective
O
oral mexiletine, 37
oritavancin, 179
oxycodone, 36
P
pain management, in painful diabetic neuropathy anticonvulsants, use of, 36
with antioxidant α-lipoic acid, 37
with electrical spinal cord stimulation, 38
with glyceryl trinitrate patch, 37
improved glycaemic control, 36
intravenous lignocaine, use of, 37
with isosorbide dinitrate spray, 37
non-pharmacological treatments, 37
opiates, use of, 36–37
with oral mexiletine, 37
topical capsaicin, application of, 37
tricyclic compounds, use of, 36
painful diabetic neuropathy, see diabetic neuropathy, distal symmetrical
Panton–Valentin leucocidin, 178
penicillin-binding proteins (PBPs), 177
percutaneous transluminal angioplasty (PTA), see diabetic vascular disease, treatment of
peripheral arterial disease (PAD), 19, see also amputation, epidemiology of, risk factors for
and cardiovascular disease (CVD)
smoking behavior, 20, 30
peripheral arterial occlusive disease (PAOD), in diabetes
adjunctive measures and managing complications, 259–260
clinical evaluation of, 251–252
using arteriography, 253–254
using Doppler devices, 252
using duplex ultrasound, 253
surgical reconstruction, 254
graft, 255–256
inflow, 255
outflow, 256–259
patient, 254–256
results of, 260–261
odile, 259
treatment options in, 261–262
INDEX

peripheral neuropathy, 380
peripheral vascular disease (PVD), 52
in Africa, 380
phenytoin, 36
pluripotential cells, 198
povidone iodine, 190
pregabalin, 36
Preservation, Amputation Care and Treatment (PACT) programme, 108
pressure ulcers, see diabetic foot ulcers
preventive foot care education program effectiveness of choice of intervention, 154
outcome measures, 154–155
sample size, 155
effects on behavior change
adherence and non-compliance, 149–150
depression, 150
transtheoretical model of, 150
for established ulcer care, 144–145
initial assessment in, 151
issue to be addressed in
aim, 145
health professional education, 146
patient education, 146–149
primary prevention
reduced incidence of ulcers and amputation, 143–144
surrogate end points, 144
secondary prevention
reduced incidence of ulcers and amputation, 144
structure of
content, 151–152
delivery, 152
group education versus individual education, 153
health professional education, 154
timing and intensity, 153–154
primary health care, for diabetic foot, see diabetes foot care service, UK perspective
Pseudomonas aeruginosa, 161
psychosocial assessment instruments
Beck depression inventory, 327
diabetic foot ulcer scale (DFS), 140
hospital anxiety and depression scale, 138, 327
mini mental score, 327
neuropathy and foot-ulcer-specific quality of life instrument, 139
NeuroQoL, 140
psychosocial adjustment to illness scale, 138
INDEX

short form SF-36 questionnaire, 139
visual analogue scale (VAS), 139
Zung self-rating depression scale, 138
Purion gel, 191

R
rifamp(inc)in, 179

S
SAD system, for diabetic foot ulcers see diabetic foot ulcers, classification
Save the Diabetic Foot Project, 365–366
education and screening procedures, 367–368
project achievements, 368–370
project problems, 370–372
Scotchcast boot, 268
Seattle diabetic foot study, 275
Smads 3 and 7, 200
Special Team Amputation Mobility Prosthetics (STAMP), 108
Staphylococcus aureus, 160 see also foot infection, in diabetes person, methicillin-resistant S.aureus
surgical diseases, 310
synercid, 179

T
telavancin, 179
tetracyclines, 179
tigecycline, 179
topical capsaicin, 37
total contact cast (TCC), see also diabetic foot ulcers, offloading therapy
instant, 350–353
totipotential cells, 198
tramadol, 36
transcutaneous oxygen tension (TcpO2) measurements, 6, 43
trimethoprim/sulphamethoxazole, 179

U
United Kingdom Prospective Diabetes Study (UKPDS), 23
University of Texas system, for diabetic foot ulcers see diabetic foot ulcers, classification

V
vacuum-assisted closure (VAC®) therapy system, see negative pressure wound therapy
Veterans Health Administration (VHA), 108, see also diabetes foot care service
Veterans Medical Programs Amendments (1992), 108
vibration perception threshold (VPT), 4, 6, 32
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 19
World Health Organisation Multinational Study of Vascular Disease in Diabetes (WHO MSVDD) study, 19
wound dressing, in diabetic person, see also diabetic foot ulcers, offloading therapy
alginate dressings, 191
factors influencing, 187
feltered foam method, 355–356
honey products, use of, 187–188
hyalofill dressing, 192–193
hydrocolloid dressings, 190–191
hydrogels, 191
iodine dressings, 189–190
kerraboot device, 193
living skin equivalents, application of, 193–194
dermagraft, 193
offloading techniques, 355
other dressings, 191–192
promogran, 191
prototype pressure relieving techniques, 356–358
secondary dressings, 191
absorbent foam sheets, 191
silver-containing dressings, 188–189
third generation dressings, 193
wound treatment, in diabetes person, see also diabetic foot ulcers; foot infection, in diabetes person; larval therapy
gene transfer therapy, 199–200, 219
clinical trial with agents, 199
potential methods to, 199
healing process
exogenous agents, role of, 218–219
growth factors, role of, 215, 217–219
hormones, role of, 215–217
risks associated with, 219–220
stem cell therapy, 200–202
categories of bone-marrow-derived cells, 200
clinical application of, 201–202